Page 166 - Drug Class Review
P. 166
Page 113 of 205
Drug Effectiveness Review Project
placebo 87% 32% 8% 8% placebo 33.3% 17%
Authors and Year: Reisberg et al. 2003; Rive et al. 2004; Doody et al. 2004
memantine 84% 18% 10% 10% No significant differences in adverse events Post randomization exclusions: NR Overall loss to follow-up: 28.2% Loss to follow-up differential high: No memantine 23.0% 10%
ITT: Yes Yes NR Method not reported Fair
Final Report Update 1 ADVERSE EVENTS: Overall adverse effects reported: Agitation • Insomnia • Diarrhea • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
